drugset / Trial / NCT01469351

Identifying Potential Effects of Liraglutide on Degenerative Changes

NCT01469351

Completed 34 enrolled University of Aarhus
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Today Alzheimers disease can not be cured. Animal experiments have shown that the hormone GLP-1 can improve memory in Alzheimer-prone mice. The investigators hypothesis is that a 6-month treatment with the GLP-1 receptor stimulating drug liraglutide will reduce the intracerebral amyloid deposition in the central nervous system (CNS) in patients with Alzheimer's disease (AD) and thereby reduce the clinical symptoms of the disease.

Timeline

Start
2012-01
Primary completion
2013-04
Completion
2013-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide 1.8 mg

Indications